A Study Evaluating the of OPC-34712 in Subjects With Normal Hepatic Function and Hepatically Impaired Subjects
A Single-dose, Open-label, Parallel Group, Matched Study Evaluating the Pharmacokinetics of Oral OPC-34712 Tablet in Subjects With Normal Hepatic Function and Hepatically Impaired Subjects
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
A PHASE1 clinical study on Schizophrenia, this trial is completed. The trial is conducted by Otsuka Pharmaceutical Development & Commercialization, Inc. and has accumulated 8 data snapshots since 2010. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE1
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE1
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE1
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
Dec 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Otsuka Pharmaceutical Development & Commercialization, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Miami, United States
- • Minneapolis, United States
- • San Antonio, United States